ArticleThe Lancet regional health. Europe2024

Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.

Gian Paolo Fadini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.